Aducanumab is a monoclonal antibody drug developed by Biogen for the treatment of Alzheimer's Disease. It is designed to target and reduce the production of amyloid-beta, a protein that accumulates in the brains of Alzheimer's patients and is thought to be a major contributor to the disease. Aducanumab is administered intravenously and is currently in Phase 3 clinical trials. Aducanumab is one of several drugs being developed to treat Alzheimer's Disease, a progressive neurological disorder that affects millions of people worldwide. Other drugs in development include solanezumab, gantenerumab, and crenezumab. These drugs are designed to target different aspects of the disease, such as reducing inflammation, improving cognitive function, and slowing the progression of the disease. Companies in the Aducanumab market include Biogen, Eli Lilly, Roche, and Novartis. These companies are researching and developing drugs to treat Alzheimer's Disease, with Aducanumab being one of the most promising. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
